Mysa Saad/X
Dec 8, 2025, 08:35
Dr. Mysa Saad Had Her First Oral Presentation at ASH25
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“Congrats to Dr. Mysa Saad on her first oral presentation at ASH25!
Post-hoc AVERT analysis: In cancer patients on apixaban prophylaxis, concurrent antiplatelet/NSAID use ↑ clinically relevant bleeding (HR 1.78) with no VTE benefit.”
Follow the latest in Hemostasis Today.
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation